Biomarker evaluation in advanced stage cervical cancer by an international working group. Tumor Stages (1B1-4). - BIO-RAIDs

Institut Curie0 个研究点目标入组 100 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•1)No prior treatment for cervical cancer.
•2)FIGO Stage IB1 to IVB; all histological subtypes (excluding neuro-endocrine type).
•3)Pelvic MRI available or planned before the start of treatment if FIGO >= IB2, and optional for IB1 stage
•4)Possibility to communicate imaging data by CD ROM (format DICOM 3.0 or more).
•5)Disease amenable to biopsy (3 tumour samples are mandatory prior to treatment).
•6)Age >= 18 years.
•7)ECOG 0-2.
•8)Life expectancy > 6 months.
•9)Patient eligible for standard treatment
•10) Patient having health care insurance.
•11) Informed and signed consent by patient.

•1)Patient enrolled in a clinical trial involving an investigative new agent.
•2)Co morbidity, preventing patient to tolerate the proposed standard treatment.
•3)Past history of invasive cancer over the 5 years preceding entry in the present trial (except basal cell carcinoma and carcinoma in situ of the cervix).
•4)Impossibility to carry out evaluation by MRI (patient claustrophobic, pacemaker, metallic implant, non availability, other), if FIGO >= IB2.
•5)Patient deprived from ability to decide on her own.
•6)Patient unable to have a regular follow up for geographical, social or psychological reasons.
•7)Pregnancy or patient old enough to procreate and not using effective contraceptive method.

发起方